Portugal
Less than half of oncologic medicinal products require authorisation from ADSE from October
Publication: PÚBLICO
Author: publico@publico.pt
Source published: 27/09/2026, 16:30:40 UTC
Briefing created: 27/09/2026, 17:52:56 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/09/2026, 17:50:25 UTC.
Briefings
A new price table mandates that 48.2% of oncological medications require prior authorization from the ADSE starting October 2026, a figure already exceeding 50.6% under the current table. This represents a significant shift in pharmaceutical access for cancer treatment, with the ADSE acting as a gatekeeper for a substantial portion of the drug portfolio.
Key points
- 48.2% of oncological medications require prior authorization from the ADSE under the new price table effective October 2026.
- The current table already requires this procedure for 50.6% of pharmaceuticals, indicating a gradual increase in regulatory hurdles.
Context and limitations
Data reflects the new price table effective October 2026; pre-existing authorization rates for the current table are not quantified.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/09/2026, 17:52:56 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeihhtqvsxpx7wwmaqgwad4zdn6v3tavwgxqanrshpawa2uyzyxflam